Purpose

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan study

Exclusion Criteria

  • With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
0.3 mg/kg zilucoplan (RA101495)
  • Drug: zilucoplan (RA101495)
    Daily subcutaneous (SC) injection

Recruiting Locations

University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
trials@rapharma.com

More Details

Status
Recruiting
Sponsor
Ra Pharmaceuticals

Study Contact

Sponsor Ra Pharmaceuticals, Inc.
+1 617 401 4060
trials@rapharma.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.